Before I talk about the inter-institutional agreement that has been confirmed with the National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), there are some key pieces regarding this 8-K that must be considered.
This piece is positively important from the Bio Matrix Scientific Group, Inc. (BMSN) 8-K that was filed with the SEC on 12/17/2015 because it confirms that regardless to what was previously considered as their portion of ownership of Regen Biopharma, Inc. (RGBP), as of 12/17/2015… in my opinion… BMSN now owns at least a 51% Controlling Interest in RGBP. Based on what was recently filed in the BMSN 8-K, such confirms that either shares have been recently moved over and/or issued into the name of BMSN or somehow shares have been re-organized to ensure that BMSN still has the ”51% controlling interest” in RGBP because it specifically stated such within the 8-K below:
Also important, per the BMSN 8-K that was filed with the SEC on 12/17/2015:
Now I think it is important to get to know a little bit more about who they have entered into an inter-institutional agreement with… National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), an agency of the U.S. Department of Health and Human Services:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.